Sequenom is an American company based in San San, California. He develops molecular technologies and highly sensitive laboratory genetic tests for NIPT. Sequenom’s subsidiary, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests for patients, including MaterniT21, plus a non-invasive prenotypic test for trisomy 21, trisomy 18, and trisomal RHrhend.

In June 2014, the company sold its block of bioscents to Bioscension for up to $ 35.8 million. In July 2016, it was announced that diagnostic and testing giant LabCorp would acquire Sequenom, paying $ 40 for each outstanding stake in Sequenom. The implementation was completed in September 2016.

History of Sequenom

On August 4, 2011, Sequenom announced that it will name its new blood test for Down Syndrome Pregnancy MaterniT21 when the product goes on sale in the United States.

On August 11, 2011, Sequenom announced a European licensing agreement with LifeCodexx. The companies agreed to collaborate on the development and launch of Trisomy 21 laboratory tests and other aneuplodies trials in Germany, Austria, Switzerland and Lie, with the potential for additional launches in other countries. Under an initial 5-year licensing agreement, Sequenom has licensed key patent rights to LifeCodexx, including European Patent EP0994963B1 and Application EP2183693A1, which enable the development and localization of a non-invasive test for aneuploidy circulating fetal cell-free DNA in maternal plasma.

On October 24, 2011, the International Society for Prenatal Diagnostics (ISPD) released a Rapid Response Statement in response to the launch of the Sequenom test of non-invasive trisomy 21 (MaterniT21).

On October 17, 2011, Sequenom announced that the clinical validation study leading to the implementation of MaterniT21 LEARS has been published in the journal Genetics in Medicine. On October 17, 2011, the Sequenom Center for Molecular Medicine announced the launch of the MaterniT21 non-invasive prenatal test for Down Syndrome.